OTC · Biotechnology

GenSight Biologics S.A. (GSGTF) Stock

$0.09 +0.00% OTC: GSGTF Healthcare

GenSight Biologics S.A. is a clinical-stage biotechnology firm dedicated to pioneering, advancing, and bringing to market treatments for serious eye and central nervous system disorders, specifically those linked to mitochondrial dysfunction and neurodegeneration.

Valuation

MetricValue
Price$0.09
Market Cap$14.67M
P/E Ratio-1.04
P/B Ratio-0.64
P/S Ratio13692.00
EPS (TTM)$-0.08
52-Week High$0.48
52-Week Low$0.09
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE42.20%
ROA-145.78%
ROCE264.76%
Gross Margin100.00%
Operating Margin—
Net Margin—
Debt/Equity-0.52
Current Ratio0.39

Annual Financials (USD)

Metric20212022202320242025
Revenue$5.0M$3.0M$1.0M$2.0M$0
Operating Profit$-28.0M$-28.0M$-30.0M$-16.0M$-12.0M
Net Profit$-29.0M$-28.0M$-26.0M$-14.0M$-12.0M
EPS$-0.63$-0.60$-0.54$-0.17$-0.08
Op Margin-533.1%-1078.0%-2343.8%-1054.2%-1170494.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$57.0M$26.0M$9.0M$11.0M$8.0M
Total Liabilities$41.0M$41.0M$40.0M$38.0M$33.0M
Cash$44.0M$11.0M$2.0M$2.0M$2.0M
Borrowings$13.0M$18.0M$24.0M$19.0M$13.0M

Latest News

GenSight Biologics Reports Cash Position as of June 30, 2026, and Provides Business Updates Business Wire · Jul 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-17.0M$-34.0M$-25.0M$-13.0M$-9.0M
Investing Cash Flow$0$0$0$0$9.0M
Financing Cash Flow$27.0M$-3.0M$-1.0M$-1.0M$-1.0M
Net Cash Flow$6.0M$-34.0M$-8.0M$0$0
Free Cash Flow$-17.0M$-34.0M$-25.0M$-13.0M$-9.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.02
EV / EBITDA-2.15
FCF Yield-61.35%
Quick Ratio0.39
Interest Coverage-11.84
Return 1Y—
Return 3Y—
Return 5Y—

Ownership

Insiders Held7.07%
Institutions Held41.19%
Institutions Float Held44.32%
Institutional HolderSharesReport Date
Fidelity Securities Fund-Fidelity OTC Portfolio210,0962026-02-28
Fidelity Securities Fund-Fidelity OTC K6 Portfolio15,3832026-02-28

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AGYTFAllergy Therapeutics plc $0.15 +0.00% -5.05 $756.30M 0.00%
AVCTFAvacta Group Plc $0.94 +3.71% -7.36 $440.30M 0.00%
BJTRFBeijing Tong Ren Tang Chinese Medicine Company Limited $0.65 +0.00% 14.49 $542.78M 7.69%
BOVNFBioInvent International AB (publ) $3.29 +0.00% -4.47 $216.40M 0.00%
BPMUFBasilea Pharmaceutica AG $60.28 +0.00% 19.58 $746.00M 0.00%

About GenSight Biologics S.A.

GenSight Biologics S.A. is a clinical-stage biotechnology firm dedicated to pioneering, advancing, and bringing to market treatments for serious eye and central nervous system disorders, specifically those linked to mitochondrial dysfunction and neurodegeneration. Their therapeutic pipeline is built upon cutting-edge gene therapy approaches, including mitochondrial targeting sequences and optogenetics technologies. The company's primary drug candidate, LUMEVOQ (GS010), is a recombinant AAV2-based gene therapy currently undergoing Phase III clinical evaluation for Leber hereditary optic neuropathy (LHON) stemming from a specific ND4 gene mutation. Another key candidate, GS030, is in Phase I/II trials for retinitis pigmentosa and is also being investigated in preclinical studies for dry age-related macular degeneration. Beyond these, GenSight is also advancing a range of other preclinical programs aimed at addressing various ophthalmic and neurodegenerative conditions. Established in 2012, GenSight Biologics S.A. operates from its headquarters in Paris, France.

GenSight Biologics S.A. is headquartered in FR.

GenSight Biologics S.A. (GSGTF) stock trades at $0.09 with a market capitalization of $14.67M. The stock is valued at a price-to-earnings (P/E) ratio of -1.04, price-to-book of -0.64, price-to-sales of 13692.00. Over the past 52 weeks the stock has ranged between $0.09 and $0.48, and currently trades 81.3% below its 52-week high.

On profitability, GenSight Biologics S.A. generates a return on equity (ROE) of 42.20% — well above the market average, a sign of a high-quality business, return on capital employed of 264.76%.

Official website: www.gensight-biologics.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides